TL;DR
The U.S. has withheld nearly $600 million in funding from Gavi, the global vaccine alliance, amid disputes over vaccine policies. This move threatens to undermine international immunization efforts, especially in low-resource countries. The situation raises concerns about increased disease risk and preventable deaths.
The United States has been withholding approximately $600 million in funding from Gavi, the global vaccine alliance, since 2024, amid disputes over vaccine policies and funding conditions. This withholding threatens to disrupt immunization programs in lower-income countries, where access to affordable vaccines is critical. The move has raised international concern about potential setbacks in global health efforts and preventable disease outbreaks.
The U.S. pledged nearly $1.6 billion to Gavi in 2024, covering about 13% of its funding through 2030. However, the State Department has not disbursed the funds for fiscal years 2025 and 2026, citing unresolved issues over vaccine safety and policy disagreements. While the Biden administration has expressed cautious optimism about resolving the dispute, officials acknowledge that no detailed data or accountability has been provided by Gavi to justify the withholding. The U.S. government has also questioned Gavi’s use of older vaccines, such as the diphtheria-tetanus-pertussis (DTwP) vaccine and thimerosal-containing vaccines, which are still recommended by the World Health Organization for low-resource settings due to their affordability and efficacy. Critics argue that the U.S. is effectively holding global immunization efforts hostage until Gavi changes its vaccine strategies, which could take years to implement.
Why It Matters
This development matters because Gavi plays a vital role in providing affordable vaccines to lower-income countries, preventing millions of childhood deaths annually. The withholding of funds risks creating immunization gaps, leading to potential outbreaks of diseases like measles, diphtheria, and pertussis. The move also signals a broader shift in U.S. foreign health policy, emphasizing vaccine safety concerns that may undermine decades of progress in global health equity. Vulnerable populations in resource-limited settings could bear the brunt of these funding disruptions, increasing health disparities worldwide.
Vaccination Record: Vaccine for adolescents and adults (Diphtheria – Tetanus – Poliomyelitis – Pertussis-Measles – Mumps – Rubella – Meningitis C – HPV – H epatitis B – Flu …)
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Background
Since its founding in 2000, Gavi has been a cornerstone of global immunization efforts, supported heavily by U.S. funding. The Biden administration’s pledge in 2024 aimed to sustain and expand vaccination coverage in developing countries. However, recent political and ideological disputes over vaccine ingredients and safety—particularly Kennedy’s anti-vaccine rhetoric—have led to the current funding impasse. Historically, the U.S. has been one of Gavi’s largest donors, and reductions in funding could have long-term impacts on immunization coverage, especially for vaccines that are less expensive or require fewer doses, which are critical in low-resource settings.
“Using cheaper vaccines like DTwP can have trade-offs, but they are essential for reaching populations with limited healthcare infrastructure.”
— Seth Berkley, infectious-disease expert and former Gavi leader
“President Trump entrusted Secretary Robert F. Kennedy Jr. to manage the U.S. relationship with Gavi.”
— U.S. State Department spokesperson
“We are cautiously optimistic about a constructive path forward, but Gavi has not yet provided the data needed for full evaluation.”
— Andrew Nixon, HHS Deputy Assistant Secretary for Media Relations
thimerosal free vaccines for low-resource settings
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What Remains Unclear
It remains unclear when or if the U.S. will release the withheld funds, and whether Gavi will modify its vaccine policies to satisfy U.S. concerns. The exact impact of the funding delay on ongoing immunization programs in specific countries is also still being assessed. Additionally, the broader implications of this dispute for global health diplomacy are yet to be determined.
affordable global vaccination kits
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What’s Next
Next steps include continued negotiations between U.S. officials and Gavi, with potential for the release of funds if agreements are reached. International health organizations are monitoring the situation closely, preparing contingency plans to mitigate vaccine coverage gaps. Congressional and diplomatic efforts may also influence the resolution, with some lawmakers advocating for the release of funds to sustain global immunization efforts.
Federal Motor Carrier Safety Regulations Pocketbook 10 Pack, Softbound, English, 5" x 7", Easy Access to FMCS Regulations, J. J. Keller & Associates, Inc.
FMCSA regulations book includes Parts 40, 380, 382, 383, 387, 390-397, 399 and Appendix G of the FMCSRs….
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Why is the U.S. withholding funds from Gavi?
The U.S. cites concerns over Gavi’s vaccine policies, including its use of older vaccines like DTwP and thimerosal-containing vaccines, which U.S. officials question for safety and policy reasons. The withholding is also linked to broader political disputes over vaccine safety and international health policy.
What impact could this have on global vaccination efforts?
The delay in U.S. funding risks reducing vaccine access in low-income countries, potentially leading to outbreaks of preventable diseases and increased childhood mortality. For more on global health emergencies, see WHO declarations. It could also undermine decades of progress in global health equity.
Could this affect vaccine availability in the U.S.?
No, the dispute primarily concerns international vaccine distribution and policies. U.S. domestic vaccination programs are largely unaffected by this funding issue.
When might the funding be restored?
It is uncertain; negotiations are ongoing. A resolution depends on Gavi addressing U.S. concerns and reaching an agreement on vaccine policies and transparency.
Source: The Atlantic
